Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

Rhea-AI Summary

Veracyte, Inc. (NASDAQ: VCYT) will release its financial results for Q2 2022 on August 2, 2022, after the market close. Following this, management will conduct a conference call at 4:30 p.m. ET to discuss results and provide a business update. The call will be accessible via the company’s website, and a replay will be available afterward. Veracyte is dedicated to improving patient care through advanced diagnostics, reducing the need for risky procedures, and expediting appropriate treatment for prevalent cancers.

Positive

• Veracyte is expanding its diagnostic tests, addressing eight of the top ten prevalent cancers in the U.S.
• The company has secured an exclusive license for a diagnostics instrument, facilitating global delivery of its tests.
• The upcoming earnings release and conference call could provide positive insights into financial performance.

Negative

• None.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday, August 2, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/xvodmkry. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.

The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BI2d52800c01ef45e7b962619638558741

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey. Our growing menu of advanced diagnostic tests help patients avoid risky, costly procedures and interventions, and reduce time to appropriate treatment. Our tests address eight of the ten most prevalent cancers by incidence in the United States. In addition to making our tests available in the United States through our central laboratories, our exclusive license to a best-in-class diagnostics instrument positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005808/en/

Investors

Shayla Gorman - Director, Investor Relations

investors@veracyte.com

(619) 393-1545

Media

Tracy Morris - Vice President of Global Corporate Communications

tracy.morris@veracyte.com

(650) 380-4413

Source: Veracyte, Inc.

FAQ

What date will Veracyte release its Q2 2022 financial results?

Veracyte will release its Q2 2022 financial results on August 2, 2022.

What time is the Veracyte Q2 2022 conference call?

The Veracyte Q2 2022 conference call is scheduled for 4:30 p.m. Eastern Time on August 2, 2022.

How can I access the Veracyte conference call?

The conference call can be accessed through the link provided on Veracyte's website.

What is Veracyte's focus in diagnostics?

Veracyte focuses on improving patient care by providing advanced diagnostic tests for prevalent cancers.

Where is Veracyte headquartered?

Veracyte is headquartered in South San Francisco, California.